Future roles for FoxM1 inhibitors in cancer treatments

Future Oncology

Volumn 3, Issue 1, 2007, Pages 1-3

  Adami, Guy R ^a   Ye, Honggang ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; DNA; NUCLEAR PROTEIN; POLO LIKE KINASE 1; POLYPEPTIDE; ROSCOVITINE; SIOMYCIN A; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR FOXM1 INHIBITOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CANCER CELL; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG TARGETING; EDITORIAL; ENZYME PHOSPHORYLATION; GENE DELETION; GENE EXPRESSION REGULATION; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER SURGERY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; TARGET CELL;

CELL DEATH; CELL DIVISION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; NEOPLASMS; PEPTIDES; PHOSPHOPROTEINS;

EID: 33847019573     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.1.1     Document Type: Editorial

References (16)

1. Laoukili J, Stahl M, Medema RH: FoxM1: at the crossroads of ageing and cancer. Biochim. Biphys. Acta 1775 (1), 92-102 (2006).
2. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmmann R: Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6, 744-750 (2004).
3. Wonsey DR, Follettie MT: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 65, 5181-5189 (2005).
4. Laoukili J, Kooistra MR, Bras A et al.: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Ced Biol. 7, 126-136 (2005).
5. Wang IC, Chen YJ, Hughes D et al.: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cksl) ubiquitin ligase. Mol. Cell. Biol. 25, 10875-10894 (2005).
6. Kalin TV, Wang IC, Ackerson TJ et al.: Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66, 1712-1720 (2006).
7. Kim IM, Ackerson T, Ramakrishna S et al.: The Forkhead Box M1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 66, 2153-2161 (2006).
8. Kalinichenko, VV, Major ML, Wang X et al.: FoxM1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 18, 830-850 (2004).
9. Eferl R, Ricci R, Kenner L et al.: Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112, 181-192 (2003).
10. Wang X, Krupczak-Hollis K, Tan Y, Dennewitz MB, Adami GR, Costa RH: Increased hepatic Forkhead Box M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration through diminished p27Kip1 protein levels and increased Cdc25B expression. J. Biol. Chem. 277, 44310-44316 (2002).
11. Walensky LD, Kung AL, Eschcr I et al.: Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004).
12. Gusarova. GA, Wang IC, Major ML et al.: A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest. 117 (1), 99-111 (2006).
13. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL: Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 66, 9731-9735 (2006).
14. Blagden S, de Bono J: Drugging cell cycle kinases in cancer therapy. Curr. Drug Targets 6, 325-335 (2005).
15. Tan Y, Raychaudhuri P, Costa RH: Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell. Biol. (2006).
16. Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6, 321-330 (2006).